Could a daily synbiotic supplement ease ulcerative colitis?

NCT ID NCT07411131

Not yet recruiting Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a new synbiotic formula (SGR11) in 50 adults with mild-to-moderate ulcerative colitis, a type of inflammatory bowel disease. Participants take the supplement daily for 8 weeks. Researchers will check if symptoms improve and if the supplement is safe, using questionnaires and stool samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGR11 synbiotic formula (a mix of probiotics and prebiotics)
What this could lead to: If it works, this could point toward a simple dietary supplement to help manage ulcerative colitis symptoms and improve gut health.
What could go wrong: This is a very small, early pilot study with only 50 people. It may not show clear benefits, and results might not apply to all IBD patients. Side effects are possible but not well-known yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASE (IBD) ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Prince of Wales Hospital

Hong Kong, Hong Kong
Prince of Wales Hospital

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.